Argenx and Zai Lab secure China approval for Vyvgart Hytrulo

Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa).

China’s medicines regulator has granted the nod for the treatment of people with chronic inflammatory demyelinating polyneuropathy. The weekly injectable is now the only approved therapy in China for the severe and often progressive autoimmune disorder.

Vyvgart Hytrulo’s approval follows successful outcomes in the ADHERE study, a double-blind, placebo-controlled trial that indicated a 69% reduced relapse risk among Chinese patients.